Downsview Ontario, Canada Clinical Trials

A listing of Downsview Ontario, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 344 clinical trials
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

Toronto Liver Centre
 (4.5 away)
  • 275 views
  • 30 Jul, 2021
  • +64 other locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Sunnybrook Health Sciences Centre
 (5.8 away)
  • 33 views
  • 03 Aug, 2021
  • +9 other locations
A Study of Biomarker-Directed Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with …

Sunnybrook Health Science Centre ( Site 0304)
 (5.8 away) Contact site
  • 352 views
  • 02 Aug, 2021
  • +92 other locations
A Safety Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA …

The Hospital for Sick Children
 (7.4 away) Contact site
  • 134 views
  • 02 Aug, 2021
  • +100 other locations
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent …

adjuvant chemotherapy
renal function
growth factor
vinflunine
erdafitinib
Princess Margaret Hospital- UHN
 (7.2 away) Contact site
  • 271 views
  • 01 Aug, 2021
  • +592 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

rituximab
bendamustine
acalabrutinib
cyclin d1
Research Site
 (5.8 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Sunnybrook Odette Cancer Centre
 (5.8 away) Contact site
  • 2496 views
  • 24 Jul, 2021
  • +209 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

neutrophil count
oropharyngeal carcinoma
pet/ct scan
cancer
human papillomavirus
University Health Network
 (7.2 away) Contact site
  • 56 views
  • 24 Jul, 2021
  • +29 other locations
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

VAY736 dose testing; VAY736 efficacy and safety testing.

adcc
Novartis Investigative Site
 (7.3 away) Contact site
  • 83 views
  • 25 Jul, 2021
  • +59 other locations
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.

The Hospital For Sick Kids
 (7.4 away) Contact site
  • 190 views
  • 04 Aug, 2021
  • +48 other locations